EPISODE · Apr 10, 2019 · 45 MIN
Episode 200 -- Brian Kaspar PhD
from Neuroscientists Talk Shop · host Neuroscientists Talk Shop
Wednesday, April 10, 2019 Brian Kaspar (AveXis Inc) talks about the realities and promise of building a single-dose gene transfer therapy for treating the prime gene defect in spinal muscular atrophy (SMA) type I. He discusses his company’s modified adeno-associated virus 9 approach to human gene therapy that is currently in highly promising clinical trials, for SMA, and in development for Rett syndrome and one variant of Amyotrophic Lateral Sclerosis. Duration: 45 minutes Discussants:(in alphabetical order) Jenny Hsieh (Semmes Foundation Chair, UTSA) Salma Quraishi (Res Asst Prof, UTSA) Charles Wilson (Ewing Halsell Chair, UTSA) acknowledgement: JM Tepper for original music.
What this episode covers
Wednesday, April 10, 2019 Brian Kaspar (AveXis Inc) talks about the realities and promise of building a single-dose gene transfer therapy for treating the prime gene defect in spinal muscular atrophy (SMA) type I. He discusses his company’s modified adeno-associated virus 9 approach to human gene therapy that is currently in highly promising clinical trials, for SMA, and in development for Rett syndrome and one variant of Amyotrophic Lateral Sclerosis. Duration: 45 minutes Discussants:(in alphabetical order) Jenny Hsieh (Semmes Foundation Chair, UTSA) Salma Quraishi (Res Asst Prof, UTSA) Charles Wilson (Ewing Halsell Chair, UTSA) acknowledgement: JM Tepper for original music.
NOW PLAYING
Episode 200 -- Brian Kaspar PhD
No transcript for this episode yet
Similar Episodes
Feb 8, 2026 ·4m
Jan 30, 2026 ·6m
Dec 15, 2025 ·2m
Nov 30, 2025 ·5m
Oct 26, 2025 ·14m
Oct 26, 2025 ·61m